세계의 이상지질혈증 시장 보고서(2025년)

Dyslipidemia is a condition in which the levels of lipids (fats) in the blood become abnormal. The goal of managing dyslipidemia is to regulate lipid levels, reduce the risk of cardiovascular diseases, and enhance heart health through a combination of lifestyle changes, medication, and regular monitoring.

The primary treatment options for dyslipidemia include statins, bile acid sequestrants, PCSK9 inhibitors, small interfering RNA (siRNA), cholesterol absorption inhibitors, fibrates, niacins, omega-3 fatty acid derivatives, and others. Statins are medications that lower cholesterol by inhibiting the enzyme HMG-CoA reductase, which is crucial for cholesterol production in the liver. These treatments are administered through various routes, such as oral and parenteral, and are distributed through various channels, including hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.

The dyslipidemia market research report is one of a series of new reports from The Business Research Company that provides dyslipidemia market statistics, including the dyslipidemia industry global market size, regional shares, competitors with the dyslipidemia market share, detailed dyslipidemia market segments, market trends, and opportunities, and any further data you may need to thrive in the dyslipidemia industry. This dyslipidemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dyslipidemia market size has grown rapidly in recent years. It will grow from $16.31 billion in 2024 to $18.08 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth observed in the historical period can be attributed to factors such as a rising genetic predisposition, an increasingly sedentary lifestyle, the growing consumption of unhealthy diets, an aging population, and escalating obesity rates.

The dyslipidemia market size is expected to see rapid growth in the next few years. It will grow to $27.04 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth anticipated during the forecast period can be attributed to factors such as advancements in lipid-lowering therapies, increased awareness and screening programs, the rising prevalence of metabolic disorders, higher healthcare expenditure, and the growing prevalence of dyslipidemia. Key trends during this period include advancements in gene therapies, innovations in RNA-based treatments, progress in AI-driven drug discovery, developments in personalized medicine, and advancements in digital health monitoring.

The growing obese population is expected to drive the expansion of the dyslipidemia market. Obesity, characterized by excess body fat that negatively impacts health, is becoming more prevalent due to lifestyle changes that cause prolonged energy imbalances, leading to gradual weight gain and associated health problems. Obesity contributes to dyslipidemia by disrupting lipid metabolism, resulting in abnormal cholesterol and triglyceride levels, which increase the risk of cardiovascular diseases. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people worldwide are affected by obesity, including 2.5 billion adults aged 18 and older. Additionally, 37 million children under five years old were classified as overweight. This rising rate of obesity is a significant driver of the dyslipidemia market.

Leading companies in the dyslipidemia market are focusing on developing advanced combination therapies to improve treatment outcomes, enhance patient adherence, and address multiple lipid imbalances simultaneously. Advanced combination therapies involve using two or more therapeutic agents in a single regimen to improve efficacy, minimize side effects, and target various mechanisms of the disease. For instance, in March 2024, Esperion Therapeutics Inc., a US-based pharmaceutical company, announced that its medications NEXLETOL (bempedoic acid) and NEXLIZET (a combination of bempedoic acid and ezetimibe) were approved by the Food and Drug Administration (FDA), a US government agency. These advanced, non-statin oral treatments are designed to lower low-density lipoprotein cholesterol (LDL-C) and reduce the risk of cardiovascular events. The updated labels for these drugs allow them to be used alone or in combination with statins, which are commonly prescribed to lower cholesterol. This flexibility is especially beneficial for patients who cannot tolerate statins or prefer non-statin treatment options.

In July 2022, NewAmsterdam Pharma Holding BV, a Netherlands-based biopharmaceutical company focused on treating dyslipidemia, entered into a merger agreement with Frazier Lifesciences Acquisition Corporation. Through this merger, NewAmsterdam aims to develop obicetrapib, a next-generation, low-dose, once-daily CETP inhibitor designed for patients with dyslipidemia who are at high risk for cardiovascular disease. Frazier Lifesciences Acquisition Corporation, a US-based healthcare company, specializes in novel therapeutics.

Major players in the dyslipidemia market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Zydus Lifesciences Ltd., Lupin Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Amarin Corporation, Esperion Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Outsource Strategies International, Catabasis Pharmaceuticals, NewAmsterdam Pharma Holding BV, JW Pharmaceutical.

North America was the largest region in the dyslipidemia market in 2024. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dyslipidemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dyslipidemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dyslipidemia market consists of revenues earned by entities by providing services such as diagnosis, lipid profile testing, medical consultations, lifestyle counseling, prescription, and advanced therapeutic interventions for managing abnormal lipid levels. The market value includes the value of related goods sold by the service provider or included within the service offering. The dyslipidemia market also includes sales of products such as ezetimibe combination drugs, adenosine triphosphate-citrate lyase (ACL) inhibitors, and bempedoic acid combination drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dyslipidemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dyslipidemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dyslipidemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dyslipidemia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Statins; Bile Acid Sequestrants; PCSK9 Inhibitors; Small Interfering RNA (siRNA); Cholesterol Absorption Inhibitors; Fibrates; Niacins; Omega-3 Fatty Acid Derivatives; Other Treatments
• 2) By Route Of Administration: Oral; Parental
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Drug Store; Online Pharmacies
• Sub Segments:
• 1) By Statins: Atorvastatin; Simvastatin; Rosuvastatin; Pravastatin
• 2) By Bile Acid Sequestrants: Cholestyramine; Colesevelam
• 3) By PCSK9 Inhibitors: Evolocumab; Alirocumab
• 4) By Small Interfering RNA (siRNA): Inclisiran
• 5) By Cholesterol Absorption Inhibitors: Ezetimibe
• 6) By Fibrates: Fenofibrate; Gemfibrozil
• 7) By Niacins: Nicotinic Acid
• 8) By Omega-3 Fatty Acid Derivatives: Eicosapentaenoic Acid (EPA); Docosahexaenoic Acid (DHA)
• 9) By Other Treatments: Herbal Supplements; Combination Therapies
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi SA; AstraZeneca plc; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Dyslipidemia Market Characteristics

3. Dyslipidemia Market Trends And Strategies

4. Dyslipidemia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Dyslipidemia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Dyslipidemia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Dyslipidemia Market Growth Rate Analysis
• 5.4. Global Dyslipidemia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Dyslipidemia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Dyslipidemia Total Addressable Market (TAM)

6. Dyslipidemia Market Segmentation

• 6.1. Global Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Statins
• Bile Acid Sequestrants
• PCSK9 Inhibitors
• Small Interfering RNA (siRNA)
• Cholesterol Absorption Inhibitors
• Fibrates
• Niacins
• Omega-3 Fatty Acid Derivatives
• Other Treatments
• 6.2. Global Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parental
• 6.3. Global Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Drug Store
• Online Pharmacies
• 6.4. Global Dyslipidemia Market, Sub-Segmentation Of Statins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atorvastatin
• Simvastatin
• Rosuvastatin
• Pravastatin
• 6.5. Global Dyslipidemia Market, Sub-Segmentation Of Bile Acid Sequestrants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cholestyramine
• Colesevelam
• 6.6. Global Dyslipidemia Market, Sub-Segmentation Of PCSK9 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Evolocumab
• Alirocumab
• 6.7. Global Dyslipidemia Market, Sub-Segmentation Of Small Interfering RNA (siRNA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inclisiran
• 6.8. Global Dyslipidemia Market, Sub-Segmentation Of Cholesterol Absorption Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ezetimibe
• 6.9. Global Dyslipidemia Market, Sub-Segmentation Of Fibrates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fenofibrate
• Gemfibrozil
• 6.10. Global Dyslipidemia Market, Sub-Segmentation Of Niacins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nicotinic Acid
• 6.11. Global Dyslipidemia Market, Sub-Segmentation Of Omega-3 Fatty Acid Derivatives, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Eicosapentaenoic Acid (EPA)
• Docosahexaenoic Acid (DHA)
• 6.12. Global Dyslipidemia Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Herbal Supplements
• Combination Therapies

7. Dyslipidemia Market Regional And Country Analysis

• 7.1. Global Dyslipidemia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Dyslipidemia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Dyslipidemia Market

• 8.1. Asia-Pacific Dyslipidemia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Dyslipidemia Market

• 9.1. China Dyslipidemia Market Overview
• 9.2. China Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Dyslipidemia Market

• 10.1. India Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Dyslipidemia Market

• 11.1. Japan Dyslipidemia Market Overview
• 11.2. Japan Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Dyslipidemia Market

• 12.1. Australia Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Dyslipidemia Market

• 13.1. Indonesia Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Dyslipidemia Market

• 14.1. South Korea Dyslipidemia Market Overview
• 14.2. South Korea Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Dyslipidemia Market

• 15.1. Western Europe Dyslipidemia Market Overview
• 15.2. Western Europe Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Dyslipidemia Market

• 16.1. UK Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Dyslipidemia Market

• 17.1. Germany Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Dyslipidemia Market

• 18.1. France Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Dyslipidemia Market

• 19.1. Italy Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Dyslipidemia Market

• 20.1. Spain Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Dyslipidemia Market

• 21.1. Eastern Europe Dyslipidemia Market Overview
• 21.2. Eastern Europe Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Dyslipidemia Market

• 22.1. Russia Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Dyslipidemia Market

• 23.1. North America Dyslipidemia Market Overview
• 23.2. North America Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Dyslipidemia Market

• 24.1. USA Dyslipidemia Market Overview
• 24.2. USA Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Dyslipidemia Market

• 25.1. Canada Dyslipidemia Market Overview
• 25.2. Canada Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Dyslipidemia Market

• 26.1. South America Dyslipidemia Market Overview
• 26.2. South America Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Dyslipidemia Market

• 27.1. Brazil Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Dyslipidemia Market

• 28.1. Middle East Dyslipidemia Market Overview
• 28.2. Middle East Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Dyslipidemia Market

• 29.1. Africa Dyslipidemia Market Overview
• 29.2. Africa Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Dyslipidemia Market Competitive Landscape And Company Profiles

• 30.1. Dyslipidemia Market Competitive Landscape
• 30.2. Dyslipidemia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Dyslipidemia Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Amgen Inc.
• 31.3. Viatris Inc.
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Daiichi Sankyo Company Limited
• 31.6. Zydus Lifesciences Ltd.
• 31.7. Lupin Pharmaceuticals Inc.
• 31.8. Alnylam Pharmaceuticals Inc.
• 31.9. Amarin Corporation
• 31.10. Esperion Therapeutics Inc.
• 31.11. Arrowhead Pharmaceuticals Inc.
• 31.12. Outsource Strategies International
• 31.13. Catabasis Pharmaceuticals
• 31.14. NewAmsterdam Pharma Holding BV
• 31.15. JW Pharmaceutical

32. Global Dyslipidemia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dyslipidemia Market

34. Recent Developments In The Dyslipidemia Market

35. Dyslipidemia Market High Potential Countries, Segments and Strategies

• 35.1 Dyslipidemia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Dyslipidemia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Dyslipidemia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer